Gabrielle Matilde Robbins

University Of Minnesota

$162,965

Attributed

$162,965

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $51.3K · FY2021–24

$100K$75K$50K$25K$0

'21

'22

'23

'24

Funding mix

By agency

NIH$162,965 · 1

By mechanism

F30$162,965 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Minnesota

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Clinical Trials”

Sonia M Thomas · Research Triangle Institute$700,865,642
Bambra Strokes · Ppd Development Lp$526,656,217
Tracy L Nolen · Research Triangle Institute$474,487,152
Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785

Research focus

Clinical TrialsChimeric Antigen Receptor T CellsAllogenicActivated Natural Killer CellAntibodiesAutoimmunityAntibody-Dependent Cell CytotoxicityBindingBioluminescenceAntigensAntigen TargetingCancer CellCancer ImmunotherapyCar T Cell TherapyCbl GeneCell KillingCell LineCell-Mediated CytolysisCell PhysiologyCellsCell TransformationChimeric Antigen ReceptorBody Weight DecreasedCoculture Techniques

Grant awards (4)

Genome Engineered Natural Killer Cell Immunotherapy against Human Osteosarcoma$46,683

F30 · FY2024 · OD · contact PI

Genome Engineered Natural Killer Cell Immunotherapy against Human Osteosarcoma$51,334

F30 · FY2023 · OD · contact PI

Genome Engineered Natural Killer Cell Immunotherapy against Human Osteosarcoma$32,931

F30 · FY2022 · OD · contact PI

Genome Engineered Natural Killer Cell Immunotherapy against Human Osteosarcoma$32,017

F30 · FY2021 · OD · contact PI